Monday's Top Biotech & Medical Stocks

by H.S. Ayoub
BioHealth Investor.com

Biotechnology

NUVELO INC NEW [NUVO] +52.69%
MEMORY PHARMACEUTICA [MEMY] +44.79%
ANTIGENICS INC [AGEN] +42.72%
CORCEPT THERAPEUTICS [CORT] +40.00%
GENETIC TECH SPON [GENE] +33.27%

Diagnostic Substances

THRESHOLD PHARMACEUT [THLD] +13.75%
IMMUNOMEDICS INC [IMMU] +6.76%
ASPENBIO PHARMA INC [APNB.OB] +4.76%
AVANT IMMUNOTHERAP [AVAN] +3.70%
INFINITY PHARMACEUTI [INFI] +2.18%

Drug Delivery

ELAN CP PLC ADR [ELN] +3.80%
MATRIXX INITIATVS [MTXX] +2.80%
BENTLEY PHARMACEUTIC [BNT] +1.27%
PENWEST PHARM CO [PPCO] +0.84%
DELCATH SYSTEMS INC [DCTH] +0.74%

Drug Manufacturers

PHARMACYCLICS INC [PCYC] +17.95%
ATHEROGENICS INC [AGIX] +13.57%
ADVANCIS PHARMA CP [AVNC] +10.13%
OSCIENT PHARMACEUT [OSCI] +7.60%
SIGA TECH INC [SIGA] +7.43%

Drug Related Products

AUXILIUM PHARMACEUT [AUXL] +3.67%
MEDICAL NUTRITN USA [MDNU.OB] +2.27%
ZILA INC [ZILA] +2.00%
NUTRACEUTICAL INTL [NUTR] +1.82%
SALIX PHARM DEL [SLXP] +1.72%

Generic Drugs

ISOLAGEN INC [ILE] +5.46%
CATALYST PHARMACEUTI [CPRX] +3.99%
PHARMACUTICAL CO [PRX] +1.16%
MYLAN LABS INC [MYL] +0.90%

Medical Appliances & Equipment

NORTH AMERN SCI [NASI] +7.62%
SIGNALIFE INC. [SGN] +7.23%
MICROTEK MED HLDGS [MTMD] +5.01%
EDAP TMS SA ADR [EDAP] +4.99%
ARRHYTHMIA RES TECH [HRT] +4.97%

Medical Instruments & Supplies

DEXCOM [DXCM] +15.58%
OPHTHALMIC IMAGING SYS INC [OISI.OB] +7.76%
ALPHATEC HOLDINGS [ATEC] +4.71%
BOVIE MEDICAL CORP [BVX] +4.53%
EP MEDSYSTEMS INC [EPMD] +4.17%

Medical Laboratories & Research

ENZO BIOCHEM INC [ENZ] +2.41%
OSI PHARMACEUTIC [OSIP] +2.30%
AETERNA ZENTARIS [AEZS] +1.75%
ARRAY BIOPHARMA IN [ARRY] +1.09%
PSYCHEMEDICS NEW [PMD] +0.86%

- Thursday's Top Biotech and Medical Stocks
- Wednesday's Top Biotech and Medical Stocks

____________________

1 Comments:

Harald Blaatand said...: So Mad Jim Cramer with Money was caught off guard with DNDN.

Will we see Cramer do the same with PGLA, when that company spikes big time on Monday April 16th ??

That is when Progen will be first trading after having released their final 48-week liver survival data in the week-end 14/15th April.

Have a look at the chart and see the spike on December 13th, 2006 when the 30-week data was released!

Progen's PI-88 compound is being fast tracked by FDA, whose recommendation to Progen was that they should go straight to Phase III trials without doing the Phase II-b trial.

That in itself will bring PI-88 to cancer suffers much earlier than first anticipated by cutting ~three years off the development cycle. (Also saving the company about $10mil in the process – (see press releases from Progen on www.progen.com.au )

About the data release on 14 th April:

PI-88 Data to be Presented at Key International Conferences

Progen Industries Limited (ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL). Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007.

In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona, Spain from April 11-15, 2007.

Dr. Anand Gautam, Progen's VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles, U.S, from April 14-18, 2007.

About Progen:
Progen Industries (Now Progen Pharmaceutical) Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.
Progen's three key areas of focus are:
•Clinical Development - via a focused clinical trial programme involving its two compounds PI-88 and PI-166.
•Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes.
•Manufacturing Services – PI-88 manufacturing development and supply for the clinical program and contract manufacturing services.

Keywords - Progen, liver cancer, PI-88

Web links to selected recent news and other information about Progen:

Progen buys back roylaty from Medigen
www.progen.com.au/?page=nepress2007.html

www.progen.com.au/?page=nepress2006.html

Prelim Results for Phase 2 liver cancer trial
www.progen.com.au/?page=nepress2006.html

PI-88 mode of action www.progen.com.au/?page=nepress2005.html

Progen's drug development pipeline www.progen.com.au/?page=pihome.html

Progen Industries Ltd www.progen.com.au; 4:57 PM